ARTICLE | Clinical News
OXP001: Phase I data
June 23, 2014 7:00 AM UTC
A single-blind, U.K. Phase I trial in 43 healthy volunteers showed that OXP001 met the primary endpoint of reducing gastric irritation as measured by mean Lanza score vs. Brufen ibuprofen (reduction o...